Study:
Phase II Study of Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Patients With Previously Untreated High-Risk or Relapsed or Refractory Multiple Myeloma
Rationale:
Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Thalidomide may stop the growth of multiple myeloma by blocking blood
flow to the cancer. Giving arsenic trioxide together with ascorbic acid, dexamethasone, and
thalidomide may kill more cancer cells.
Purpose:
This phase II trial is studying how well giving arsenic trioxide together with
ascorbic acid, dexamethasone, and thalidomide work in treating patients with multiple
myeloma.
Study Status: Withdrawn
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Refractory Plasma Cell Neoplasm |
Drug: arsenic trioxide
Drug: ascorbic acid
Drug: dexamethasone
Drug: thalidomide
Procedure: anti-cytokine therapy
Procedure: antiangiogenesis therapy
Procedure: biological therapy
Procedure: chemotherapy
Procedure: drug resistance inhibition
Procedure: growth factor antagonist therapy
Procedure: non-specific immune-modulator therapy |
Phase 2 |
Verified by
The Cleveland Clinic
December, 2006
Sponsored by: The Cleveland Clinic
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00112879
Study Type: Interventional
Study Design: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Mohamad A. Hussein, MD., Study Chair